NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

$28.30

-0.06 (-0.21 %)

(As of 07/29/2021 01:33 PM ET)

Add

Compare

Today's Range

$28.00

▼

$28.62

50-Day Range

$27.73

▼

$41.67

52-Week Range

$27.10

▼

$72.79

Volume15,597 shs

Average Volume1.04 million shs

Market Capitalization$1.76 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.04

30 days | 90 days | 365 days | Advanced Chart

Receive GBT News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. The company was founded in 2011 and is headquartered in South San Francisco, California.

GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 27, 2021 | finance.yahoo.com

Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
July 22, 2021 | finance.yahoo.com

Global Blood Therapeutics (NASDAQ:GBT) Sets New 12-Month Low at $29.85
July 22, 2021 | americanbankingnews.com

GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
July 22, 2021 | finance.yahoo.com

Hedge Funds Continue Dumping Global Blood Therapeutics Inc (GBT)
July 21, 2021 | finance.yahoo.com

Global Blood Therapeutics (NASDAQ:GBT) Sets New 1-Year Low at $31.88
July 15, 2021 | americanbankingnews.com

First Week of August 20th Options Trading For Global Blood Therapeutics (GBT)
July 14, 2021 | nasdaq.com

Global Blood Therapeutics (NASDAQ:GBT) Trading 4.5% Higher
July 8, 2021 | americanbankingnews.com

Global Blood Therapeutics: Return On Capital Employed Insights
July 1, 2021 | benzinga.com

Why Global Blood Therapeutics Moved Higher Wednesday
July 1, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GBT
Previous Symbol
CUSIPN/A
CIK1629137
Webwww.gbt.com
Phone650-741-7700
Employees389
Year FoundedN/A

Sales & Book Value

Annual Sales$123.80 million
Price / Sales14.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.73 per share
Price / Book4.21

Profitability

EPS (Most Recent Fiscal Year)($4.04)
Net Income$-247,550,000.00
Net Margins-167.73%
Return on Equity-57.58%
Return on Assets-35.81%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares62,267,000
Market Cap$1.76 billion
Next Earnings Date8/3/2021 (Confirmed)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.55 out of 5 stars

Medical Sector

896th out of 2,214 stocks

Pharmaceutical Preparations Industry

436th out of 869 stocks

3.3 Analyst's Opinion

Consensus Rating
Global Blood Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $80.50, Global Blood Therapeutics has a forecasted upside of 184.5% from its current price of $28.30.
Amount of Analyst Coverage
Global Blood Therapeutics has only been the subject of 4 research reports in the past 90 days.

3.8 Community Rank

Outperform Votes
Global Blood Therapeutics has received 548 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Global Blood Therapeutics has received 180 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Global Blood Therapeutics has received 75.27% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote “Outperform” if you believe GBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Global Blood Therapeutics does not currently pay a dividend.
Dividend Growth
Global Blood Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Global Blood Therapeutics insiders have sold 105.03% more of their company's stock than they have bought. Specifically, they have bought $18,980.00 in company stock and sold $38,915.00 in company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Global Blood Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Global Blood Therapeutics are expected to grow in the coming year, from ($4.61) to ($3.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Global Blood Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Global Blood Therapeutics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Global Blood Therapeutics has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions

Is Global Blood Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Global Blood Therapeutics?

Wall Street analysts have given Global Blood Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Global Blood Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Global Blood Therapeutics.

How can I listen to Global Blood Therapeutics' earnings call?

Global Blood Therapeutics will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its earnings results on Tuesday, May, 4th. The company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.01) by $0.20. The firm earned $39.04 million during the quarter, compared to analyst estimates of $42.88 million. Global Blood Therapeutics had a negative net margin of 167.73% and a negative trailing twelve-month return on equity of 57.58%.
View Global Blood Therapeutics' earnings history.

How has Global Blood Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GBT stock has decreased by 48.8% and is now trading at $28.11.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GBT?

15 analysts have issued 1 year price objectives for Global Blood Therapeutics' shares. Their forecasts range from $36.00 to $152.00. On average, they anticipate Global Blood Therapeutics' stock price to reach $80.50 in the next year. This suggests a possible upside of 186.4% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:

Dr. Ted W. Love, Pres, CEO & Director (Age 62, Pay $1.13M)
Mr. Jeffrey S. Farrow, CFO & Principal Accounting Officer (Age 59, Pay $694.31k)
Ms. Patricia Borga Suvari, Chief Legal Officer & Sec. (Age 60, Pay $641.5k)
Ms. Jung E. Choi, Chief Bus. & Strategy Officer (Age 51, Pay $657.12k)
Mr. David L. Johnson, Chief Commercial Officer (Age 52, Pay $702.75k)
Dr. David R. Phillips, Founder & Advisor
Dr. Matthew P. Jacobson, Founder & Advisor
Dr. Andrej Sali, Founder & Advisor
Ms. Nazila Habibizad, Sr. VP of Operations
Stephanie Yao, Sr. Director of Corp. Communications & Investor Relations

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Global Blood Therapeutics' key competitors?

Some companies that are related to Global Blood Therapeutics include Evotec (EVTCY), Perrigo (PRGO), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), I-Mab (IMAB), Sarepta Therapeutics (SRPT), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), Arvinas (ARVN), Ionis Pharmaceuticals (IONS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Schrödinger (SDGR), Reata Pharmaceuticals (RETA) and Cassava Sciences (SAVA).
View all of GBT's competitors.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $28.11.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics has a market capitalization of $1.75 billion and generates $123.80 million in revenue each year. The company earns $-247,550,000.00 in net income (profit) each year or ($4.04) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 389 workers across the globe.

What is Global Blood Therapeutics' official website?

The official website for Global Blood Therapeutics is www.gbt.com.

Where are Global Blood Therapeutics' headquarters?

Global Blood Therapeutics is headquartered at 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]

This page was last updated on 7/29/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here